Oct 8 (Reuters) - InnoCare Pharma Ltd 688428.SS:
ZENAS BIOPHARMA AND INNOCARE PHARMA ANNOUNCE LICENSE AGREEMENT GRANTING ZENAS RIGHTS FOR THREE AUTOIMMUNE PRODUCT CANDIDATES, INCLUDING ORELABRUTINIB, A BTK INHIBITOR IN PHASE 3 DEVELOPMENT FOR MULTIPLE SCLEROSIS
ZENAS BIOPHARMA: ANNOUNCES $120 MILLION PRIVATE PLACEMENT FINANCING
ZENAS BIOPHARMA INC - NOVEL ORAL IL-17AA/AF INHIBITOR, AND AN ORAL, BRAIN-PENETRANT, TYK2 INHIBITOR, EXPECTED TO BEGIN PHASE 1 CLINICAL TRIALS IN 2026
ZENAS BIOPHARMA: TO PAY INNOCARE UPFRONT & NEAR-TERM MILESTONE PAYMENTS UP TO $100 MILLION IN CASH